MROH2B

Across TCGA pan-cancer cohorts, MROH2B Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated MROH2B data layer compared with 18 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher MROH2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MROH2B expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

ACC, UCEC, and ESCA are the cancer types where MROH2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.145	0.888	<.001	45	view →
UCEC	DFS	Median	All	0.764	0.626	.005	34	view →
ESCA	OS	Median	All	0.359	0.717	.001	24	view →
COAD	OS	Median	III,IV	0.220	0.789	<.001	21	view →
HNSC	DFS	Median	IV	0.737	0.295	.011	7	view →
DLBC	OS	Median	All	0.054	0.842	<.001	6	view →
SKCM	OS	Median	IV	0.311	0.777	.001	6	view →
SCLC	DFS	Median	All	0.228	0.472	.025	3	view →
LGG	DFS	Median	All	0.173	0.455	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

MROH2B–ACC (OS)

Open the ACC breakdown →